Search

Your search keyword '"Calle, Roberto A."' showing total 237 results

Search Constraints

Start Over You searched for: Author "Calle, Roberto A." Remove constraint Author: "Calle, Roberto A."
237 results on '"Calle, Roberto A."'

Search Results

1. Repeatability of MRI Biomarkers in Nonalcoholic Fatty Liver Disease: The NIMBLE Consortium.

2. Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis.

5. ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials

8. Supplementary Methods 1 from A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia

9. Supplementary Table S2 from A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia

10. Data from A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia

11. Supplementary Figure S4 from A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia

14. A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia

17. El juego como estrategia de aprendizaje en el aula

19. Abstract CT108: First-in-patient study of the GDF-15 inhibitor ponsegromab in patients with cancer and cachexia: Safety, tolerability, and exploratory measures of efficacy

20. A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects

21. The Nimble Stage 1 Study Validates Diagnostic Circulating Biomarkers for Nonalcoholic Steatohepatitis

23. Peformance of fibrometer-derived biomarker panels for assessment of fibrosis stage in NAFLD: NIMBLE stage 1 and the NASH CRN collaborative Study

24. Results of the Non-invasive Biomarkers of Metabolic Liver Disease (NIMBLE) study 1.1 on the reproducibility and repeatability of shear-wave and transient elastography in non-alcoholic fatty liver disease

25. Validation of the ADAPT score for the diagnosis of clinically significant fibrosis in patients with non-alcoholic fatty liver disease (NAFLD)

31. Optimización de la productividad en líneas de producción de gas natural aplicando protección anticorrosiva en pozos someros de alta presión

32. Cálculo del Ebitda en función de la rentabilidad de la Distribuidora Droguería las Américas S.A.C 2016 - 2020

34. Reproducibility and Repeatability of US Shear-Wave and Transient Elastography in Nonalcoholic Fatty Liver Disease

37. Remote Digital Monitoring for Medical Product Development

38. Abstract 3056: Growth differentiation factor 15 (GDF-15) inhibition attenuates platinum-based chemotherapy-induced emesis, anorexia and weight loss and increases survival

40. Growth differentiation factor 15 (GDF-15) as a key regulator of cachexia induced by platinum-based chemotherapy.

43. EL GRAN EXPERIMENTO. POR QUÉ FALLAN LAS DEMOCRACIAS DIVERSAS Y CÓMO HACER QUE FUNCIONEN.

45. 453_Supplementary_Fig1 – Supplemental material for Efficacy of ertugliflozin in monotherapy or combination therapy in patients with type 2 diabetes: A pooled analysis of placebo-controlled studies

50. Immunocytochemical localization of alpha-protein kinase C in rat pancreatic beta-cells during glucose-induced insulin secretion

Catalog

Books, media, physical & digital resources